Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tolerion Inc.

www.tolerioninc.com

Latest From Tolerion Inc.

Diabetes vaccine a step closer?

A vaccine that can prevent the damage to pancreatic β-cells in patients with type I diabetes has long been the Holy Grail of diabetes research.

Metabolic Disorders

Gene therapy: a technology whose time has come?

It is now almost 20 years since the first patient was enrolled into an officially sanctioned gene therapy study, and in that time the field has been through a series of successes and setbacks. Today, it remains the case that only two gene therapy products have ever been approved anywhere in the world, but interest in gene therapy remains keen.

Gastrointestinal Cardiovascular

New appointment at Versartis

Versartis (US), an emerging biotechnology company developing therapeutics for metabolic diseases and endocrine disorders, has appointed Paul Westberg senior vice-president of business development. He was most recently vice-president of business development at Bayhill Therapeutics, and has also worked at Collabra Pharma, Deltagen and Genentech. Versartis is planning to initiate its first clinical trial of its lead product candidate VRS-859 in type 2 diabetes in the second half and to have top-line results by the end of the year.

Metabolic Disorders Companies

Genentech to pay up to $350 million for Bayhill's diabetes candidate

Genentech is to pay the US private biopharmaceutical company Bayhill Therapeutics $25 million up-front and potential milestones of more than $325 million to develop and commercialise BHT-3021, a DNA-based antigen specific immunotherapy in Phase I/II clinical trials in patients with type 1 diabetes.

Metabolic Disorders Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Bayhill Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tolerion Inc.
  • Senior Management
  • Contact Info
  • Tolerion Inc.
    Phone: (650) 575-1702
    321 Dedalera Dr.
    Portola Valley, CA 94028
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register